- Validating MCM2 as a clinically relevant surrogate immunohistochemical marker for an aggressive meningioma molecular subtype.
Validating MCM2 as a clinically relevant surrogate immunohistochemical marker for an aggressive meningioma molecular subtype.
Journal of neuropathology and experimental neurology (2023-10-15)
Allison Shelbourn, Nicholas Nuechterlein, Carolina Angelica Parada, Jessica Eaton, Mallory Tucker, Manuel Ferreira, Patrick J Cimino
PMID37837323